Management of Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients: A Systematic Review

2012 ◽  
Vol 10 (6) ◽  
pp. 531-543 ◽  
Author(s):  
Joshua Rubin ◽  
◽  
Noel Ayoub ◽  
Fady Kaldas ◽  
Sammy Saab
Keyword(s):  
Hepatocellular Carcinoma ◽  
Systematic Review ◽  
Liver Transplant ◽  
Transplant Recipients ◽  
Recurrent Hepatocellular Carcinoma ◽  
Liver Transplant Recipients

Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients with Hepatitis C

2010 ◽  
Vol 43 (2) ◽  
pp. 229-235 ◽  
Author(s):  
Ivan Zendejas-Ruiz ◽  
Alan W. Hemming ◽  
Chaoru Chen ◽  
Jason J. Schwartz ◽  
John B. Sorensen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Transplant Recipients ◽  
Recurrent Hepatocellular Carcinoma ◽  
Liver Transplant Recipients

Recurrent hepatocellular carcinoma in liver transplant recipients: Parameters affecting time to recurrence, treatment options and survival in the sorafenib era

2011 ◽  
Vol 97 (4) ◽  
pp. 436-441 ◽  
Author(s):  
Tulio EF Pfiffer ◽  
Daniel Seehofer ◽  
Annett Nicolaou ◽  
Ruth Neuhaus ◽  
Hanno Riess ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplant ◽  
Treatment Options ◽  
Transplant Recipients ◽  
Recurrent Hepatocellular Carcinoma ◽  
Time To Recurrence ◽  
Liver Transplant Recipients

scholarly journals Peritoneal Dialysis After Liver Transplantation: A Systematic Review

2021 ◽  
Vol 8 ◽  
pp. 205435812110297
Author(s):  
Jean Maxime Côté ◽  
Isabelle Ethier ◽  
Héloïse Cardinal ◽  
Marie-Noëlle Pépin
Keyword(s):  
Systematic Review ◽  
Liver Transplantation ◽  
Liver Transplant ◽  
Kidney Failure ◽  
Liver Graft ◽  
Transplant Recipients ◽  
Technique Survival ◽  
Liver Transplant Recipients

Background: Chronic kidney disease following liver transplantation is a major long-term complication. Most liver transplant recipients with kidney failure will be treated with dialysis instead of kidney transplantation due to noneligibility and shortage in organ availability. In this population, the role of peritoneal dialysis (PD) as a modality of kidney replacement therapy (KRT) remains unclear. Objective: To determine the feasibility regarding safety, technique survival, and dialysis efficiency of PD in liver transplant recipients requiring KRT for maintenance dialysis. Design: Systematic review. Setting: Interventional and observational studies reporting the use of PD after liver transplantation. Patients: Adult liver transplant recipients with kidney failure treated with maintenance KRT. Measurements: Extracted data included eligibility criteria, study design, demographics, and PD modality. The following outcomes of interest were extracted: rate of peritonitis and microorganisms involved, noninfectious peritoneal complications, technique survival, and kidney transplantation-censored technique survival. Non-PD complications included overall survival, liver graft dysfunction, and hospitalization rate. Methods: The following databases were searched until July 2020: MedLine/PubMed, EMBASE, CINAHL, and Cochrane Library. Two reviewers independently screening all titles and abstracts of all identified articles. Due to the limited sample size, observational designs and study heterogeneity expected, no meta-analysis was pre-planned. Descriptive statistics were used to report all results. Results: From the 5263 identified studies, 4 were included in the analysis as they reported at least 1 outcome of interest on a total of 21 liver transplant recipients, with an overall follow-up duration on PD of 19.0 (Interquartile range [IQR]: 9.5-29.5) months. Fifteen episodes of peritonitis occurred in a total cumulative PD follow-up of 514 patient-months, representing an incidence rate of 0.35 per year. These episodes did not result in PD technique failure, mortality, or impairment of liver graft function. Limitations: Limitations include the paucity of studies in the field and the small number of patients included in each report, a risk of publication bias and the impossibility to directly compare hemodialysis to PD in this population. These results, therefore, must be interpreted with caution. Conclusions: Based on limited data reporting the feasibility of PD in liver transplant recipients with kidney failure, no signal was associated with an increased risk of infectious complications. Long-term studies evaluating this modality need to be performed. Registration (PROSPERO): CRD42020218374.

scholarly journals Endocarditis in Liver Transplant Recipients: A Systematic Review

2021 ◽  
Vol 10 (12) ◽  
pp. 2660
Author(s):  
Petros Ioannou ◽  
Konstantinos Alexakis ◽  
Diamantis P. Kofteridis
Keyword(s):  
Systematic Review ◽  
Liver Transplant ◽  
Pulmonary Valve ◽  
Cochrane Library ◽  
Transplant Recipients ◽  
Treatment Data ◽  
Liver Transplant Recipients ◽  
Culture Negative ◽  
Overall Mortality ◽  
Significant Mortality

Infective Endocarditis (IE) is associated with significant mortality. Interestingly, IE in patients with liver transplantation has not been adequately described. The aim of this review was to systematically review all published cases of IE in liver transplant recipients and describe their epidemiology, microbiology, clinical characteristics, treatment and outcomes. A systematic review of PubMed, Scopus and Cochrane Library (through 2nd January 2021) for studies providing epidemiological, clinical, microbiological, treatment data and outcomes of IE in liver transplant recipients was conducted. A total of 39 studies, containing data for 62 patients, were included in the analysis. The most common causative pathogens were gram-positive microorganisms in 69.4%, fungi in 25.8%, and gram-negative microorganisms in 9.7% of cases, while in 9.3% IE was culture-negative. The aortic valve was the most commonly infected valve followed by mitral, tricuspid and the pulmonary valve. Aminoglycosides, vancomycin and aminopenicillins were the most commonly used antimicrobials, and surgical management was performed in half of the cases. Clinical cure was noted in 57.4%, while overall mortality was 43.5%. To conclude, this systematic review thoroughly describes IE in liver transplant recipients and provides information on epidemiology, clinical presentation, treatment and outcomes.

The interplay between gut microbiota and the immune system in liver transplant recipients and its role in infections

2021 ◽  
Author(s):  
Giuseppe Ancona ◽  
Laura Alagna ◽  
Andrea Lombardi ◽  
Emanuele Palomba ◽  
Valeria Castelli ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Immune System ◽  
Liver Disease ◽  
Gut Microbiota ◽  
Liver Transplant ◽  
Bacterial Infections ◽  
Multidrug Resistant ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

Liver transplantation (LT) is a life-saving strategy for patients with end-stage liver disease, hepatocellular carcinoma and acute liver failure. LT success can be hampered by several short-term and long-term complications. Among them, bacterial infections, especially due to multidrug-resistant germs, are particularly frequent with a prevalence between 19 and 33% in the first 100 days after transplantation. In the last decades, a number of studies have highlighted how gut microbiota (GM) is involved in several essential functions to ensure the intestinal homeostasis, becoming one of the most important virtual metabolic organs. GM works through different axes with other organs, and the gut-liver axis is among the most relevant and investigated ones. Any alteration or disruption of GM is defined as dysbiosis. Peculiar phenotypes of GM dysbiosis have been associated to several liver conditions and complications, such as chronic hepatitis, fatty liver disease, cirrhosis and hepatocellular carcinoma. Moreover, there is growing evidence of the crucial role of GM in shaping the immune response, both locally and systemically, against pathogens. This paves the way to the manipulation of GM as a therapeutic instrument to modulate the infectious risk and outcome. In this minireview we provide an overview of the current understanding on the interplay between gut microbiota and the immune system in liver transplant recipients and the role of the former in infections.

scholarly journals Letter: the effect of sirolimus on recurrence and survival in liver transplant recipients with hepatocellular carcinoma-authors’ reply

2018 ◽  
Vol 48 (11-12) ◽  
pp. 1331-1332
Author(s):  
Krishna V. Menon ◽  
Abdul R. Hakeem ◽  
Nigel D. Heaton
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplant ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

scholarly journals Current Interventions to Improve Adherence to Immunosuppressants in Liver Transplant Recipients: a Systematic Review

2016 ◽  
Vol 18 (1) ◽  
pp. 17-26
Author(s):  
So Hee Kim ◽  
Young Joo Lee ◽  
Sun Young Lee ◽  
Sang Hui Chu
Keyword(s):  
Systematic Review ◽  
Liver Transplant ◽  
Transplant Recipients ◽  
Liver Transplant Recipients

P.04.14 HEPATOCELLULAR CARCINOMA AND SMOKING ARE INDEPENDENT RISK FACTORS FOR DEVELOPMENT OF DE-NOVO EXTRAHEPATIC TUMORS IN LIVER TRANSPLANT RECIPIENTS

2019 ◽  
Vol 51 ◽  
pp. e177
Author(s):  
L. Gaeta ◽  
G. Cordone ◽  
A. Telese ◽  
F.P. Picciotto ◽  
A. Galeota Lanza ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Transplant ◽  
De Novo ◽  
Transplant Recipients ◽  
Independent Risk Factors ◽  
Liver Transplant Recipients

scholarly journals Hepatocellular Carcinoma Is a Negative Predictor of Sustained Viral Response in Liver Transplant Recipients With Hepatitis C Treated With Direct-Acting Antivirals

2020 ◽  
Vol 52 (8) ◽  
pp. 2450-2453 ◽  
Author(s):  
Tomasz Cieciura ◽  
Arkadiusz Urbanowicz ◽  
Bartosz Foroncewicz ◽  
Ewa Hryniewiecka ◽  
Leszek Pączek ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Sustained Viral Response ◽  
Transplant Recipients ◽  
Direct Acting Antivirals ◽  
Viral Response ◽  
Direct Acting ◽  
Liver Transplant Recipients ◽  
Negative Predictor
Sign in / Sign up

Export Citation Format

Share Document